Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

12.3K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Design of Right-Handed D-Sulfonyl-γ-AApeptides with Broad-Spectrum Antimicrobial Activity.

Journal of medicinal chemistry·2026
Same author

Sulfonyl-γ-AAs as Turn Templates Inducing β-Sheet Conformation in Macrocyclic Peptides.

Journal of the American Chemical Society·2026
Same author

α/Sulfonyl-γ-AApeptide foldamers mitigate Alzheimer's disease pathology by stabilizing transient helical domains in Aβ.

Nature communications·2026
Same author

Inhibition of Wnt Signaling Using Axin Peptidomimetics through Direct Targeting of β-Catenin.

Journal of medicinal chemistry·2026
Same author

Structural-Functional Customization of Nanoscale Liposome-in-Liposome Systems: Precision Engineering Methodology and Artificial-Intelligence-Driven Design Prospects.

Research (Washington, D.C.)·2026
Same author

Cyclic γ-AApeptide-Based Molecular Glues for RNA m<sup>6</sup>A Editing.

ACS chemical biology·2026

相关实验视频

Updated: Jun 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K

通过同时抑制激酶活性和降解蛋白质来向致癌性RET激酶.

Yafeng Wang1, Xueqing Hu2, Shriya Pandey2

  • 1Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States.

Journal of medicinal chemistry
|December 26, 2024
PubMed
概括

一种新的PROTAC降解剂,YW-N-7,同时抑制和消耗瘤原RET蛋白,为RET改变的癌症提供了一种新策略. 这种双重作用增强了抗癌疗效,甚至加强了现有的治疗方法.

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

相关实验视频

Last Updated: Jun 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • 重组转移期间 (RET) 激酶是RET改变癌症的关键标.
  • 已批准的RET抑制剂,如selpercatinib可以增加瘤性RET蛋白水平,可能会限制疗效.
  • 存在对同时抑制和降低瘤性RET蛋白水平的治疗方法的需求.

研究的目的:

  • 开发针对瘤性RET蛋白的蛋白质溶解向合体 (PROTAC) 降解剂.
  • 为了研究一种新型化合物,YW-N-7,其对RET激酶的双重作用.
  • 在癌症模型中评估同时抑制和降解RET的治疗潜力.

主要方法:

  • 开发针对瘤性RET的PROTAC降解剂.
  • 在体外和体内对化合物YW-N-7的评估.
  • 蛋白质组分析以评估特异性.
  • 在细胞培养中对YW-N-7与LOXO-292结合的评估.
  • 在KIF5B-RET驱动的异种移植瘤模型中进行测试.

主要成果:

  • 化合物YW-N-7表现出双重作用,选择性地抑制和耗尽RET蛋白.
  • 蛋白质组分析证实YW-N-7对RET的高特异性.
  • 减少与YW-N-7的RET融合蛋白增强了selpercatinib (LOXO-292) 的活性.
  • 在体内,YW-N-7在抑制KIF5B-RET驱动的异种移植瘤方面表现出显著的疗效.

结论:

  • YW-N-7是一种新型的PROTAC降解剂,具有对瘤性RET的双重抑制和消耗活性.
  • 同时抑制和降解RET激酶是一种可行的治疗策略,用于RET改变的癌症.
  • 通过克服当前RET抑制剂的局限性,YW-N-7有望改善癌症治疗.